English
Published: 2016-11-23 10:00:00 CET
Nasdaq Nordic
Investor News

Nasdaq Stockholm Welcomes Alligator Bioscience to the Main Market

Stockholm, November 23, 2016 — Nasdaq (Nasdaq: NDAQ) announced that Alligator Bioscience AB (short name: ATORX), a small cap company within the health care sector, has started trading of its shares on the main market of Nasdaq Stockholm. Alligator Bioscience is the 72nd company to list at Nasdaq’s Nordic markets* in 2016.

Alligator is a research-based biotechnology company developing antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies and is primarily active in the early phases of drug development, from the idea stage to clinical phase II trials. Alligator Bioscience was founded in 2001 and is headquartered at Medicon Village in Lund, Sweden. For more information, please visit www.alligatorbioscience.se

“We are very excited about getting listed at Nasdaq Stockholm, and taking the company to the next level,” said Per Norlén, CEO of Alligator Bioscience AB.  “We are a small company but very focused and skilled in what we do, and our ambition is to develop best and first in class tumor-directed immunotherapies. We regard the IPO as an important step in realizing this strategy.”

“We are thrilled to welcome Alligator Bioscience to the Nasdaq Stockholm main market,” said Adam Kostyál, senior vice president and head of European listings at Nasdaq. “We continue to see an inflow of health care sector companies leveraging the public market as a platform for future growth, and we look forward to supporting Alligator Bioscience for many years to come.”

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.


About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of $10.0 trillion and approximately 18,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

Media Relations Contact:
Erik Granström
+46 73 449 78 07
erik.granstrom@nasdaq.com
 

 


20161123_Alligator Bioscience_bell.jpg